文献速递肝病

抑制促胰液素/促胰液素受体轴改善NAFLD表型

Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
PubMed 文献 · Hepatology · 2021-07-29

该研究在人类NAFLD/NASH肝样本和高脂饮食小鼠中观察到胆管SCT/SCTR表达升高、miR-125b降低,伴随胆管/肝细胞衰老、胆管反应和血管生成;Sct或Sctr敲除可减轻这些表型并降低肝细胞脂合成基因Elovl1表达,提示靶向该轴可能改善NAFLD/NASH。

要点

  • NAFLD/NASH中胆管SCT/SCTR表达升高而miR-125b降低。
  • Sct或Sctr敲除减轻高脂饮食小鼠肝脂肪变、衰老和血管生成。
  • miR-125b靶向脂合成基因Elovl1,Sct/Sctr敲除后其表达下降。

核心结论

  • 胆管SCT/SCTR/miR-125b轴通过上调脂质生物合成基因Elovl1促进肝脂肪变。
  • 靶向胆管SCT/SCTR/miR-125b轴可能是改善人类NAFLD/NASH表型的关键。

研究设计与样本

  • 4周龄雄性野生型、Sct-/-和Sctr-/-小鼠喂食对照饮食或高脂饮食16周。
  • 检测人类NAFLD/NASH肝样本和高脂饮食小鼠肝中SCT/SCTR/miR-125b轴表达。
  • 用定制RT2 Profiler PCR阵列和荧光素酶试验筛选并验证miR-125b靶向的肝细胞脂合成基因。

主要发现

  • 人类NAFLD/NASH样本和高脂饮食小鼠肝中胆管SCT/SCTR表达增加而miR-125b表达降低。
  • 人类NAFLD/NASH样本和高脂饮食小鼠中观察到胆管/肝细胞衰老、胆管反应和肝血管生成,Sct-/-和Sctr-/-高脂饮食小鼠中这些表现减少。
  • Elovl1是miR-125b靶向的脂合成基因,Sct或Sctr敲除后高脂饮食小鼠肝细胞中其表达降低。
  • 野生型与Sct-/-/Sctr-/-小鼠之间粪便胆汁酸谱变化最大。

临床怎么用

  • 胆管SCT/SCTR/miR-125b轴及下游Elovl1可作为NAFLD/NASH的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Human NAFLD is characterized at early stages by hepatic steatosis, which may progress to NASH when the liver displays microvesicular steatosis, lobular inflammation, and pericellular fibrosis. The secretin (SCT)/secretin receptor (SCTR) axis promotes biliary senescence and liver fibrosis in cholestatic models through down-regulation of miR-125b signaling. We aim to evaluate the effect of disrupting biliary SCT/SCTR/miR-125b signaling on hepatic steatosis, biliary senescence, and liver fibrosis in NAFLD/NASH. APPROACH AND RESULTS: In vivo, 4-week-old male wild-type, Sct-/- and Sctr-/- mice were fed a control diet or high-fat diet (HFD) for 16 weeks. The expression of SCT/SCTR/miR-125b axis was measured in human NAFLD/NASH liver samples and HFD mouse livers by immunohistochemistry and quantitative PCR. Biliary/hepatocyte senescence, ductular reaction, and liver angiogenesis were evaluated in mouse liver and human NAFLD/NASH liver samples. miR-125b target lipogenesis genes in hepatocytes were screened and validated by custom RT2 Profiler PCR array and luciferase assay. Biliary SCT/SCTR expression was increased in human NAFLD/NASH samples and in livers of HFD mice, whereas the expression of miR-125b was decreased. Biliary/hepatocyte senescence, ductular reaction, and liver angiogenesis were observed in human NAFLD/NASH samples as well as HFD mice, which were decreased in Sct-/- and Sctr-/- HFD mice. Elovl1 is a lipogenesis gene targeted by miR-125b, and its expression was also decreased in HFD mouse hepatocytes following Sct or Sctr knockout. Bile acid profile in fecal samples have the greatest changes between wild-type mice and Sct-/- /Sctr-/- mice. CONCLUSION: The biliary SCT/SCTR/miR-125b axis promotes liver steatosis by up-regulating lipid biosynthesis gene Elovl1. Targeting the biliary SCT/SCTR/miR-125b axis may be key for ameliorating phenotypes of human NAFLD/NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chen L, Wu N, Kennedy L, et al. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology. 2021. PMID: 33928675. doi:10.1002/hep.31871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。